Drug intelligence / Profile preview

Power-TIL LM303

Development stage: Unknown
Lead developer: Suzhou Lanma Medical Technology
Modality: Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

Power-TIL LM303 is a genetically modified tumor-infiltrating lymphocyte (TIL) cell therapy being developed by Suzhou Lanma Medical Technology Co. Ltd. for the treatment of advanced solid tumors, including non-small cell lung cancer and uterine cervical cancer. Unlike conventional TIL therapies, LM303 is genetically engineered to enhance anti-tumor activity and overcome the immunosuppressive tumor microenvironment, although the specific genetic modifications have not been publicly disclosed. It is currently being evaluated in exploratory clinical studies to assess its safety, efficacy, and immunoreactivity in patients with refractory solid tumors.

Other names: LM303 InjectionLM-303 InjectionLM 303 Injection

Beyond the preview

Go deeper on Power-TIL LM303.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Power-TIL LM303.